Rho kinase inhibitors

US10624882B2 · kind B2 · utility

Assignee

• Aerie Pharmaceuticals, Inc. · US

Inventors

• Todd Bosanac · New Milford, US
• John David Ginn · New Milford, US
• Eugene Richard Hickey · Danbury, US
• Thomas Martin Kirrane, Jr. · Danbury, US
• Weimin Liu · Sandy Hook, US
• Anthony S. Prokopowicz · Stormville, US
• Sabine Schlyer · New Milford, US
• Cheng-Kon Shih · Danbury, US
• Roger John Snow · Danbury, US
• Michael Robert Turner · Danbury, US
• Frank Wu · Shandong, CN
• Erick Richard Roush Young · Danbury, US

Key dates

• Filing date: Dec 29, 2017
• Grant date: Apr 21, 2020
• Expiry date: Dec 29, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.